Insights from BioCina
From process development to commercial manufacturing, learn more through our library of resources provided by our team of industry experts.
Featured Resource
About BioCina
Learn about BioCina’s superior FDA and cGMP approved manufacturing development and manufacturing services.
What’s next for mRNA after COVID-19?
Discover how mRNA is expanding beyond vaccines into protein, antibody, gene, and cell therapies. BioCina shares strategies for delivery, design, and GMP manufacturing.
The pandemic proved that mRNA-based vaccines could be developed, manufactured, and distributed globally in record time. But the real promise of mRNA is only beginning to unfold. Developers are now targeting mRNA applications across therapeutic areas from rare disease and oncology to gene and cell therapy.
In this article, BioCina experts explore the post-pandemic future of mRNA and share strategies to unlock its next phase of therapeutic potential. Topics covered include:
- Emerging applications in protein replacement, antibody therapy, and gene editing
- How mRNA is simplifying adoptive cell therapy and ex vivo delivery
- Design and manufacturing considerations for novel RNA formats
- Challenges in scale-up, regulatory alignment, and global delivery
- How BioCina enables mRNA programs with integrated, flexible GMP manufacturing
With advanced capabilities in mRNA, pDNA, LNP encapsulation, and fill–finish, BioCina is uniquely positioned to support the next generation of mRNA-based therapies.
Access the article here:
Expanding LNP Applications Beyond mRNA Vaccines
Explore how BioCina is enabling advanced LNP-based therapies beyond mRNA vaccines, with expert insight into targeting, formulation, and therapeutic expansion.
Lipid nanoparticles (LNPs) have transformed how we deliver mRNA. But their role in modern medicine is just beginning.
In this new expert-authored article, BioCina explores how LNPs are being engineered to deliver a wider range of payloads, including siRNA, gene-editing systems, peptides, and small molecules, across therapeutic areas from oncology to neurology.
In this article, learn about:
- Strategies to optimize LNP targeting, biodistribution, and stability
- Applications in gene silencing, CAR-T, chronic disease, and more
- How thermal-stable LNPs can improve global access and reduce logistics costs
- BioCina’s integrated capabilities across mRNA, pDNA, LNPs, and GMP production
Discover how a platform born for vaccines is now powering the next generation of advanced therapies.
Access the article here:
Integrated mRNA–LNP Manufacturing as a Platform for Innovation
In BioCina’s latest article, Vice President of Business Development and Commercial Operations, Dr. Jan Bekker, explains how BioCina is developing an end-to-end RNA–LNP platform that combines microbial, plasmid DNA, mRNA, and lipid nanoparticle capabilities under one roof.
Thousands of mRNA-based vaccines and therapies are in development, but progressing from discovery to clinical trials is far from simple. Developers need more than just capacity; they require a partner who can integrate complex workflows, ensure quality, and speed up timelines.
In BioCina’s latest article, Vice President of Business Development and Commercial Operations, Dr. Jan Bekker, explains how BioCina is developing an end-to-end RNA–LNP platform that combines microbial, plasmid DNA, mRNA, and lipid nanoparticle capabilities under one roof.
Inside the article:
- Why outsourcing to an integrated CDMO is critical for mRNA–LNP programs
- How BioCina’s foundation in plasmid DNA, microbial biologics, and sterile injectables enables a seamless expansion into RNA manufacturing
- What the new GMP infrastructure in Adelaide means for clients developing both pandemic-scale and personalized therapies
- How BioCina is preparing for the future of personalized cancer vaccines and next-generation nucleic acid therapies
With seamless support from plasmid creation to fill-finish, and the benefit of up to a 48.5% tax rebate in Australia, BioCina helps innovators reduce risk, save time, and confidently reach clinical milestones.
See how BioCina is shaping the future of RNA-based therapeutics.
Access the article here:
Integrated to Accelerate: Seamless End-to-End Biomanufacturing
In BioCina’s latest article, senior leaders share how the company’s unified CDMO platform eliminates traditional handoffs, enabling biotech innovators to scale smarter and reach patients faster. With operations spanning from pDNA and mRNA to blow–fill–seal and aseptic vial/syringe fill, BioCina brings true integration to biomanufacturing.
Speed, complexity, and quality—it’s no longer enough to pick two.
In BioCina’s latest article, senior leaders share how the company’s unified CDMO platform eliminates traditional handoffs, enabling biotech innovators to scale smarter and reach patients faster. With operations spanning from pDNA and mRNA to blow–fill–seal and aseptic vial/syringe fill, BioCina brings true integration to biomanufacturing.
Inside the article:
- Why integration across drug substance and drug product matters more than ever
- How BioCina’s Adelaide and Perth sites now function as one global CDMO ecosystem
- What infrastructure upgrades mean for mRNA, LNP, microbial, and sterile injectables
- How a client-first approach leads to a 95% on-time, in-full delivery rate
These integration benefits combined with the myriad benefits of manufacturing in Australia, including Up to 48.5% tax rebate for clinical manufacturing, BioCina is able to offer incredible market value for its clients.
See how BioCina is helping clients move from molecule to market without missed beats.
Access the article here:
Australia as a Strategic Gateway: The Economic and Regulatory Advantages of Clinical Manufacturing Down Under
In this new expert-authored article, BioCina explores why Australia is emerging as a global hub for biomanufacturing and how sponsors can benefit from its combination of tax rebates, regulatory efficiency, and advanced biopharma infrastructure.
Biopharmaceutical companies are under mounting pressure to move faster, spend less, and ensure global compliance all without compromising innovation. This is especially true in clinical-stage manufacturing, where timelines and capital efficiency are everything.
In this new expert-authored article, BioCina explores why Australia is emerging as a global hub for biomanufacturing and how sponsors can benefit from its combination of tax rebates, regulatory efficiency, and advanced biopharma infrastructure.
Highlights include:
- Australia’s 48.5% tax incentive and how it substantially lowers clinical costs
- Regulatory pathways that eliminate IND requirements and reduce start-up time
- How BioCina’s Adelaide and Perth facilities enable seamless development for microbial, pDNA, LNP and mRNA programs, from drug substance through fill–finish
- The role of Australia’s national clinical trial network and digital health infrastructure in supporting faster, more efficient programs
With decades of operational excellence and Big Pharma heritage, BioCina is helping global clients turn Australia into a launchpad for clinical and commercial success.
Access the article here:
The Six Keys to Client Satisfaction in Biologics CDMO Services
This article explores the significant opportunities within the biologics contract development and manufacturing organisation (CDMO) industry to optimise client satisfaction by meeting the critical demands of discerning clients. Six key facets are identified as pivotal to success, while underscoring the fundamental role of a client-centric approach and the importance of building and nurturing strong client relationships.
Credit: Innovations in Pharmaceutical Technology, Spring 2024, pages 22-24. © Samedan Ltd.